A simple spatial alternation task for assessing memory function in zebrafish

F. Williams,Donald B. White,W. Messer

DOI: https://doi.org/10.1016/S0376-6357(02)00025-6

IF: 1.729

2002-06-28

Behavioural Processes

Abstract:

What problem does this paper attempt to address?

The Prognostic Values of the Peroxiredoxins Family in Ovarian Cancer

Saisai Li,Xiaoli Hu,Miaomiao Ye,Xueqiong Zhu

DOI: https://doi.org/10.1042/bsr20180667

2018-01-01

Bioscience Reports

Abstract:Purpose: Peroxiredoxins (PRDXs) are a family of antioxidant enzymes with six identified mammalian isoforms (PRDX1-6). PRDX expression is up-regulated in various types of solid tumors; however, individual PRDX expression, and its impact on prognostic value in ovarian cancer patients, remains unclear. Methods: PRDXs family protein expression profiles in normal ovarian tissues and ovarian cancer tissues were examined using the Human Protein Atlas database. Then, the prognostic roles of PRDX family members in several sets of clinical data (histology, pathological grades, clinical stages, and applied chemotherapy) in ovarian cancer patients were investigated using the Kaplan-Meier plotter. Results: PRDXs family protein expression in ovarian cancer tissues was elevated compared with normal ovarian tissues. Meanwhile, elevated expression of PRDX3, PRDX5, and PRDX6 mRNAs showed poorer overall survival (OS); PRDX5 and PRDX6 also predicted poor progression-free survival (PFS) for ovarian cancer patients. Furthermore, PRDX3 played significant prognostic roles, particularly in poor differentiation and late-stage serous ovarian cancer patients. Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+ Platin chemotherapy. PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy. Furthermore, PRDX3 and PRDX5 indicated lower OS in patients treated with these three chemotherapeutic agents. PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy. Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.
Review article: indeterminate colitis – definition, diagnosis and management

W. Tremaine

DOI: https://doi.org/10.1111/j.1365-2036.2006.03159.x

2006-12-06

Abstract:The term indeterminate colitis is imprecise and without a generally accepted definition. Nevertheless, it is a term that is commonly used by gastroenterologists, pathologists and surgeons.
The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

Aifeng Chen,Shibiao Ding,Xiaoqiang Shen,Xuai Lin

DOI: https://doi.org/10.1155/2021/9932088

IF: 2.809

2021-01-01

Computational and Mathematical Methods in Medicine

Abstract:Objective The aim of the study is to explore the prognosis value of PTPRH in patients with lung adenocarcinoma (LUAD). Methods Oncomine, UALCAN, and GEPIA databases were employed to examine the differential expression of PTPRH between LUAD and adjacent tissues. 100 pairs of LUAD and adjacent tissue samples were involved in this study. qRT-PCR and immunohistochemical staining were performed. Meanwhile, we analyzed The Cancer Genome Atlas (TCGA) data to investigate the correlation between PTPRH gene expression and clinicopathological characteristics. Kaplan-Meier analysis and univariate and multivariate Cox analyses were performed to estimate the relationship between PTPRH expression and LUAD prognosis. The evaluation performance was verified by drawing a ROC curve. In addition, through GSEA, the changes of PTPRH expression were analyzed by GSEA to screen out primarily affected signaling pathway. Results Oncomine, UALCAN, and GEPIA databases showed that the mRNA expression of PTPRH in LUAD tissues was significantly higher than that in adjacent tissues. qRT-PCR and immunohistochemical staining indicated the mRNA and protein levels of PTPRH in LUAD tissues were markedly upregulated. TCGA data showed that the expression of PTPRH was significantly correlated with T stage and disease stage. Kaplan-Meier analysis showed that the patients with high PTPRH expression had a poor prognosis. Univariate and multivariate Cox analyses exhibited that PTPRH expression could act as an independent prognostic factor for LUAD. The ROC curve showed that PTPRH combined with various clinicopathological features could effectively predict the prognosis of LUAD. Finally, GSEA indicated that changes in PTPRH expression level may affect p53, VEGF, Notch, and mTOR cancer-related signaling pathways. Conclusion Our results demonstrated that PTPRH was highly expressed in LUAD and may be closely correlated with the poor prognosis of LUAD patients.
The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis

Yajun Shen,Zixuan You,Lingyu Li,Xiaofei Tang,Xiaofeng Shan

DOI: https://doi.org/10.1002/ijc.34999

2024-05-15

International Journal of Cancer

Abstract:What's new? Stress‐induced expression of peroxiredoxin 1 (PRDX1) is suspected of facilitating the progression of oral squamous cell carcinoma (OSCC). The role of PRDX1 in OSCC, however, remains uncertain. Here, the authors investigated the effect of PRDX1 on OSCC progression via cytoskeletal remodeling, a process fundamental to tumor metastasis. Analyses show that PRDX1 interacts with Cofilin, specifically inhibiting serine 3 phosphorylation. In a tongue cancer xenograft mouse model, these effects were found to promote cytoskeletal reconstruction and to accelerate cell migration. The findings identify a contributory role for PRDX1 in OSCC progression and highlight PRDX1 as a potential therapeutic target. Peroxiredoxin 1 (PRDX1) is an important member of the peroxiredoxin family (PRDX) and is upregulated in a variety of tumors. Previous studies have found that high PRDX1 expression is closely related to the metastasis of oral squamous cell carcinoma (OSCC), but the specific molecular mechanism is elusive. To elucidate the role of PRDX1 in the metastasis process of OSCC, we evaluated the expression of PRDX1 in OSCC clinical specimens and its impact on the prognosis of OSCC patients. Then, the effect of PRDX1 on OSCC metastasis and cytoskeletal reconstruction was explored in vitro and in nude mouse tongue cancer models, and the molecular mechanisms were also investigated. PRDX1 can directly interact with the actin‐binding protein Cofilin, inhibiting the phosphorylation of its Ser3 site, accelerating the depolymerization and turnover of actin, promoting OSCC cell movement, and aggravating the invasion and metastasis of OSCC. In clinical samples and mouse tongue cancer models, PRDX1 also increased lymph node metastasis of OSCC and was negatively correlated with the phosphorylation of Cofilin; PRDX1 also reduced the overall survival rate of OSCC patients. In summary, our study identified that PRDX1 may be a potential therapeutic target to inhibit OSCC metastasis.

oncology
The Prognosis Of Peroxiredoxin Family In Breast Cancer

Gang Wang,Wan-Chao Zhong,Yi-Hui Bi,Si-Yue Tao,Hai Zhu,Hai-Xing Zhu,A-Man Xu

DOI: https://doi.org/10.2147/CMAR.S229389

2019-11-15

Cancer Management and Research

Abstract:Gang Wang, 1, * Wan-Chao Zhong, 2, * Yi-Hui Bi, 3 Si-Yue Tao, 4 Hai Zhu, 5 Hai-Xing Zhu, 6 A-Man Xu 1 1 Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230001, People's Republic of China; 2 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, People's Republic of China; 3 Department of Basic and Clinical Pharmacology, School of Pharmacy, Anhui Medical University, Hefei 230001, People's Republic of China; 4 Department of Orthopaedics, Anhui Provincial Hospital Affiliated with Anhui Medical University, Hefei, Anhui 230001, People's Republic of China; 5 Department of Gastrointestinal Surgery, Department Of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei 230001, People's Republic of China; 6 Department of Gastrointestinal Surgery, Anhui Provincial Cancer Hospital, Hefei 230001, People's Republic of China *These authors contributed equally to this work Correspondence: A-Man Xu Department of General Surgery, The Fourth Affiliated Hospital of Anhui Medical University, Hefei 230001, People's Republic of China Email amanxuahmu@126.com Purpose: PRDX (Peroxiredoxin) family has involved in breast cancer tumorigenesis from the evidence obtained from cell lines, human tissues and mouse models. Nonetheless, the diversified expression patterns, coupled with the prognostic values of PRDX family, still require explanation. This study aimed at investigating the clinical importance and biological of PRDXs in breast cancer. Patients and methods: Specimens of paraffin sections used for immunohistochemistry were collected from the hospital and the remaining patient information was retrieved from online databases. The expression and survival data of PRDXs in patients with breast cancer were from ONCOMINE, GEPIA, Kaplan–Meier Plotter. cBioPortal, Metascape, String, Cytoscape and DAVID were used to predict functions and pathways of the changes in PRDXs and their frequently altered neighbor genes. Immunohistochemistry was used to detect the expression of PRDXs in breast cancer. Results: We discovered the expression levels of PRDX1-5 were higher in breast cancer tissues than in normal tissues, whereas the expression level of PRDX6 was observed as lower in the former one in comparison with that of the latter one. There existed a correlation between the expression levels of PRDX4, 5 and the advanced tumor stage. Survival analysis revealed that the expression of PRDXs were all associated with relapse-free survival (RFS) in all of the patients with breast cancer. Eventually, we discovered significant regulation of the cellular oxidant detoxification and detoxification of ROS by the PRDX changes, together with obtaining the core modules of genes (TXN, TXN2, TXNRD1, TXNRD2, GPX1 and GPX2) linked to the PRDX family of genes in breast cancer. Conclusion: The PRDX family is widely involved in the development of breast cancer and affects the prognosis of patients. The functions and pathways of the changes in PRDXs and their frequently altered neighbor genes can be further verified by wet experiments. Keywords: PRDXs, breast cancer, prognosis, Kaplan-Meier plot

oncology
Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer

Rui Xu,Jiadong Pan,Jie Mei,Qinglin Zhang

DOI: https://doi.org/10.1155/2020/3948183

2020-01-09

BioMed Research International

Abstract:The peroxiredoxin (PRDX) gene family has been reported to participate in regulating occurrence and development of cancerous diseases, but its exact prognostic values in gastric cancer (GC) remain largely elusive. In the current research, we evaluated the prognostic value in predicting overall survival (OS) of each individual PRDX mRNA expression based on patients’ cohorts from the Kaplan–Meier (KM) plotter database, which contains clinical information and gene expression data obtained from a total of 876 GC patients. Our results revealed that mRNA expressions of PRDX1, PRDX2, PRDX3, and PRDX4 were significantly associated with worse OS in GC patients, whereas PRDX5 and PRDX6 mRNA expressions were not associated with OS in GC patients. In addition, the prognostic values of PRDXs in the different clinicopathological features according to clinical stages, Lauren classifications, HER2 expression status, differentiation degree, and treatment strategies of GC patients were further evaluated in the KM plotter database. As a result, more potential beneficiaries who may benefit from prognostic assessment using PRDX mRNA expressions were identified. Our results elucidated the exact values of PRDXs in assessing GC prognosis and might provide primary evidence for further study on the mechanism of PRDXs participating in occurrence and development of GC.

biotechnology & applied microbiology,medicine, research & experimental
Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival

Meilin Ye,Ting Liu,Shanshan Liu,Rong Tang,Hongrui Liu,Fan Zhang,Shenglei Luo,Minqi Li

DOI: https://doi.org/10.1038/s41420-023-01720-7

2023-11-25

Cell Death Discovery

Abstract:Abstract Peroxiredoxin 1 (Prdx1), a vital antioxidant enzyme, has been proven to play an important role in the occurrence and development of cancers, but its effects on oral squamous cell carcinoma (OSCC) remain unclear. Here, we performed bioinformatics analysis and immunohistochemical (IHC) staining to confirm that Prdx1 was higher in OSCC tissues than in normal tissues. Consistently, RT-PCR and Western blot showed elevated Prdx1 expression in OSCC cell lines compared to human oral keratinocytes (HOK), which could be knockdown by small interfering RNA (siRNA) and Lentiviral vector delivery of short hairpin RNA (shRNA). Prdx1 silencing significantly blocked OSCC cell proliferation and metastasis, as evidenced by the CCK8, colony formation, in vivo tumorigenesis experiment, wound healing, transwell assays, and changes in migration-related factors. siPrdx1 transfection increased intracellular reactive oxygen species (ROS) levels and provoked pyroptosis, proved by the upregulation of pyroptotic factors and LDH release. Prdx1 silencing ROS-independently blocked autophagy. Mature autophagosome failed to form in the siPrdx1 group. Up-regulated autophagy limited pyroptosis triggered by Prdx1 deficiency, and down-regulated pyroptosis partly reversed siPrdx1-induced autophagy defect. Collectively, Prdx1 regulated pyroptosis in a ROS-dependent way and modulated autophagy in a ROS-independent way, involving the crosstalk between pyroptosis and autophagy.

cell biology
Peroxiredoxin 2 as a potential prognostic biomarker associated with angiogenesis in cervical squamous cell cancer

Ke Zhao,Tingkuan Zhao,Runfeng Yang,Jing Liu,Min Hu

DOI: https://doi.org/10.3892/ol.2024.14461

2024-05-17

Oncology Letters

Abstract:Peroxiredoxins (Prxs) are a ubiquitously expressed family of antioxidant enzymes that either facilitate or inhibit tumorigenesis, depending on the cancer type and Prx isoform. Prx2 is a typical Prx that has a dual role in tumorigenesis and tumor progression. However, the expression of Prx2 and its precise role in cervical cancer remains to be elucidated. Therefore, the present study aimed to investigate the expression of Prx2 and its association with the progression and prognosis of cervical squamous cell cancer (CSCC). In the present study, the clinicopathological data of 105 patients diagnosed with CSCC were collected from the medical record system at Jingzhou Central Hospital, Tongji Medical College of Huazhong University of Science and Technology (Jingzhou, China). Prx2 protein was also detected in 105 CSCC tissues and 40 adjacent peri‐tumoral tissues by immunohistochemical staining. The relationships between Prx2 expression and clinicopathological features, vascular endothelial growth factor A (VEGF‐A) expression and micro‐vessel density (MVD) in CSCC were then analyzed. Progression‐free survival (PFS) was also assessed using both univariate and multivariate analyses. The results of the present study demonstrated that the expression of Prx2 was upregulated in CSCC tissues compared with the adjacent peri‐tumoral tissues (P 0.05). Furthermore, increased Prx2 expression was associated with high MVD (P=0.016), while expression of VEGF‐A was not associated with Prx2 expression (P>0.05). Kaplan‐Meier analysis showed that patients with high Prx2 expression (log‐rank test, P=0.039), high MVD (log‐rank test, P=0.015), a higher FIGO stage (log‐rank test, P=0.021) and LN metastasis (log‐rank test, P=0.022) had a shorter PFS time than patients with low Prx2 expression, low MVD, a lower FIGO stage and without LN metastasis, respectively. Cox proportional hazard regression analysis revealed that expression of Prx2 [hazard ratio (HR), 2.551; 95% confidence interval (CI), 1.056‐6.162; P=0.037], MVD (HR, 2.436; CI, 1.034‐5.735; P=0.042) and FIGO stage (HR, 1.543; CI, 1.027‐2.319; P=0.037) were independent factors for PFS time. In conclusion, the results of the present study suggested that Prx2 could act as a potential biomarker for predicting CSCC progression and prognosis and could be a novel target for antiangiogenic therapy of CSCC.

oncology
A Systematic Pan-Cancer Analysis of PXDN As a Potential Target for Clinical Diagnosis and Treatment

Xiaohu Zhou,Qiang Sun,Chang Xu,Zheng Zhou,Xiaoquan Chen,Xiuping Zhu,Zhaoshuai Huang,Weilin Wang,Yanjun Shi

DOI: https://doi.org/10.3389/fonc.2022.952849

IF: 4.7

2022-01-01

Frontiers in Oncology

Abstract:Peroxidasin (PXDN), also known as vascular peroxidase-1, is a newly discovered heme-containing peroxidase; it is involved in the formation of extracellular mesenchyme, and it catalyzes various substrate oxidation reactions in humans. However, the role and specific mechanism of PXDN in tumor are unclear, and no systematic pan-cancer studies on PXDN have been reported to date. This study employed data from multiple databases, including The Cancer Genome Atlas and The Genotype-Tissue Expression, to conduct a specific pan-cancer analysis of the effects of PXDN expression on cancer prognosis. Further, we evaluated the association of PXDN expression with DNA methylation status, tumor mutation burden, and microsatellite instability. Additionally, for the first time, the relationship of PXDN with the tumor microenvironment and infiltration of fibroblasts and different immune cells within different tumors was explored, and the possible molecular mechanism of the effect was also discussed. Our results provide a comprehensive understanding of the carcinogenicity of PXDN in different tumors and suggest that PXDN may be a potential target for tumor immunotherapy, providing a new candidate that could improve cancer clinical diagnosis and treatment.
Erythroblast transformation‐specific‐related gene promotes metastasis of oral squamous cell carcinoma by transcriptionally upregulating peroxiredoxin 1

Yujia Gu,Xue Chen,Mei Tian,Ke Liu

DOI: https://doi.org/10.1111/jop.13544

2024-05-28

Journal of Oral Pathology and Medicine

Abstract:Background Some studies confirmed that erythroblast transformation‐specific‐related gene (ERG) may be a pathogenic factor of oral squamous cell carcinoma (OSCC). However, the undergoing molecular mechanism has not been elucidated yet. Objective In this study, the investigation will focus on how the transcription factor ERG modulates the biological behaviors of OSCC. Methods In this study, cancer tissue specimens and corresponding paracancer tissues were collected from 54 patients. Real‐time polymerase chain reaction analysis and Western blots were employed to detect the expression of multiple genes. Cell proliferation assays, Transwell, and flow cytometry assay were utilized to detect the proliferation, invasion, and apoptosis of OSCC cell, respectively. Dual luciferase reporter gene and chromatin immunoprecipitation assays were conducted to verify the regulation of ERG on PRDX1. Results ERG exhibits high expression levels in OSCC. Inhibition of ERG has been shown to effectively suppress the malignant growth of OSCC cells. Moreover, ERG has been found to transcriptionally upregulate the expression of PRDX1. The knockdown of PRDX1 has demonstrated its ability to inhibit the malignant growth of OSCC cells. Interestingly, when PRDX1 is overexpressed, it attenuates the inhibitory effect of si‐ERG on the malignant growth of OSCC cells. This suggests that PRDX1 may play a crucial role in mediating the impact of ERG on malignancy in OSCC cells. Conclusion The transcription factor ERG promotes the expression of PRDX1, which could enhance the proliferation and invasion while inhibiting the apoptosis of OSCC cells.

dentistry, oral surgery & medicine,pathology
The Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor microenvironment in Hepatocellular carcinoma

Guoxu Fang,Qinghua Zhang,Jianhui Fan,Zongren Ding,Jun Fu,Yijun Wu,Yongyi Zeng,Jingfeng Liu

DOI: https://doi.org/10.21203/rs.3.rs-1644201/v1

2022-01-01

Abstract:Abstract Hepatocellular carcinoma (HCC) is a particularly heterogeneous tumor. It has a very poor prognosis. Pyroptosis has been demonstrated in recent years to be an inflammatory form of programmed cell death. However, the relationship between the expression of pyroptosis related genes (PRGs) and prognosis of HCC is still unclear. The development of a specific PRGs prognostic model is important if we want to improve therapeutic effect of tumor. In this study, we identified 42 PRGs that were differentially expressed between HCC and peripheral normal tissues and exhibited the mutation frequency, classification, the location of copy number variation (CNV) alteration and the CNV variation frequency of PRGs. Two clusters were distinguished by the consensus clustering analysis based on the 42 differentially expressed genes (DEGs). The result show that there were significant differences in clinical features (including T stage, grade, gender, stage) among different clusters. KM curve analysis show that cluster 1 had a better prognosis than cluster 2. The prognostic value of PRGs for survival was evaluated to construct a multigene signature using The Cancer Genome Atlas (TCGA) cohort. By applying the univariate analysis and multivariate analysis method, a 10-gene signature was built and all HCC patients in the TCGA cohort were divided into low-risk group and high-risk group. HCC patients in the high-risk group showed significantly lower survival possibilities than those in the low-risk group (P<0.001). Utilizing the median risk score from the TCGA cohort, HCC patients from Gene Expression Omnibus (GEO) cohort (GSE14520) were divided into two risk subgroups. The result showed that overall survival (OS) time was decreased in the high-risk group (P=0.027). Combined with the clinical characteristics, the risk score was found to be an independent factor for predicting the OS of HCC patients. Then, for evaluating the prognostic prediction value of the model, ROC curve and survival analysis were performed. Finally, we constructed a PRGs clinical characteristics nomogram to furtherly predict HCC patient survival probability. There were significant differences in immune cell infiltration, GSEA enrichment pathway, IC50 of chemotherapeutics, PRGs mutation frequency, GO and KEGG analysis between high-risk group and low-risk group. This work suggests PRGs signature plays a crucial role in HCC. The exploration may assist in identifying novel biomarkers and assist HCC patients in predicting their prognosis, clinical diagnosis, and management.
Integrative analysis the characterization of peroxiredoxins in pan-cancer

Lei Gao,Jialin Meng,Chuang Yue,Xingyu Wu,Quanxin Su,Hao Wu,Ze Zhang,Qinzhou Yu,Shenglin Gao,Song Fan,Li Zuo

DOI: https://doi.org/10.1186/s12935-021-02064-x

IF: 6.429

2021-07-10

Cancer Cell International

Abstract:Abstract Background Peroxiredoxins (PRDXs) are an antioxidant enzymes protein family involved in several biological functions such as differentiation, cell growth. In addition, previous studies report that PRDXs play critical roles in the occurrence and development of carcinomas. However, few studies have conducted systematic analysis of PRDXs in cancers. Therefore, the present study sought to explore the molecular characteristics and potential clinical significance of PRDX family members in pan cancer and further validate the function of PRDX6 in bladder urothelial carcinoma (BLCA). Methods A comprehensive analysis of PRDXs in 33 types of cancer was performed based on the TCGA database. This involved an analysis of mRNA expression profiles, genetic alterations, methylation, prognostic values, potential biological pathways and target drugs. Moreover, both the gain and loss of function strategies were used to assess the importance and mechanism of PRDX6 in the cell cycle of BLCA. Result Analysis showed abnormal expression of PRDX1-6 in several types of cancer compared to normal tissues. Univariate Cox proportional hazard regression analysis showed that expression levels of PRDX1, PRDX4 and PRDX6 were mostly associated with poor survival of OS, DSS and PFI, and PRDX2 and PRDX3 with favorable survival. In addition, the expression of PRDX genes were positively correlated with CNV and negatively with methylation. Moreover, analysis based on PharmacoDB dataset showed that the augmented levels of PRDX1, PRDX3 and PRDX6 were significantly correlated with EGFR/VEGFR inhibitor drugs. Furthermore, knocking down of PRDX6 inhibited growth of cancer cells through the JAK2-STAT3 in bladder cell lines. Conclusions PRDXs are potential biomarkers and therapeutic targets for several carcinomas, especially for BLCA. In addition, PRDX6 could regulate proliferation of cancer cell via JAK2-STAT3 pathway and involve into the process of cell cycle in BLCA.

oncology
Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor Microenvironment in Hepatocellular Carcinoma

Fang Guoxu,Zhang Qinghua,Fan Jianhui,Li Haitao,Ding Zongren,Fu Jun,Wu Yijun,Zeng Yongyi,Liu Jingfeng

DOI: https://doi.org/10.1186/s12885-022-10097-2

IF: 4.638

2022-01-01

BMC Cancer

Abstract:Little is known on the relationship between the expression of pyroptosis related genes (PRGs) and prognosis of hepatocellular carcinoma (HCC). In this study, a specific PRGs prognostic model was developed with an aim to improve therapeutic efficiency among HCC patients. In total, 42 PRGs that were differentially expressed between HCC tissues and adjacent tissues and we exhibited the mutation frequency, classification, the location of copy number variation (CNV) alteration and the CNV variation frequency of PRGs. Two clusters were distinguished by the consensus clustering analysis based on the 42 differentially expressed genes (DEGs). There were significant differences in clinical features including T stage, grade, gender, and stage among different clusters. Kaplan–Meier curve analysis showed that cluster 1 had a better prognosis than cluster 2. The prognostic value of PRGs for survival was evaluated to construct a multigene signature using The Cancer Genome Atlas (TCGA) cohort. Based on the univariate analysis and multivariate analysis, a 10-gene signature was built and all HCC patients in the TCGA cohort were divided into low-risk group and high-risk group. HCC patients in the high-risk group showed significantly lower survival possibilities than those in the low-risk group ( P < 0.001). Utilizing the median risk score from the TCGA cohort, HCC patients from International Cancer Genome Consortium (ICGC)-LIRI-JP cohort and Gene Expression Omnibus (GEO) cohort (GSE14520) were divided into two risk subgroups. The result showed that overall survival (OS) time was decreased in the high-risk group. Combined with the clinical characteristics, the risk score was an independent factor for predicting the OS of HCC patients. Then, ROC curve and survival analysis were performed to evaluate the prognostic prediction value of the model. Finally, we constructed a PRGs clinical characteristics nomogram to further predict HCC patient survival probability. There were significant differences in immune cell infiltration, GSEA enrichment pathway, IC50 of chemotherapeutics, PRGs mutation frequency between high-risk group and low-risk group. This work suggests PRGs signature played a crucial role in predicting the prognosis, infiltration of cancer microenvironment, and sensitivity of chemotherapeutic agents.
Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma

Monika Szeliga

DOI: https://doi.org/10.1016/j.neuint.2021.105256

Abstract:Gliomas are a histologically and molecularly heterogeneous group of neoplasms accounting for 80% of malignant primary brain tumors. Growing evidence suggests that production of reactive oxygen species (ROS) is linked to glioma pathogenesis, although it is still unclear whether it is a cause or an effect of this process. Peroxiredoxins (PRDXs), a family of six antioxidant proteins, may promote or inhibit carcinogenesis, depending on the tumor type and stage. The current knowledge on their expression, regulation and functions in glioma is scarce. In this study, a comprehensive analysis of PRDXs expression in distinct glioma subtypes and non-tumor brain tissues was conducted using gene expression data from The Cancer Genome Atlas (TCGA), REpository for Molecular BRAin NeoplasiaDaTa (REMBRANDT), The Chinese Glioma Atlas (CGGA) and Gene Expression Omnibus (GEO) datasets. The association between gene expression and patient survival was investigated. DNA methylation, mutations, copy number alterations of deregulated PRDXs as well as the correlation between gene expression and tumor-infiltrating immune cells were assessed. The analysis revealed overexpression of PRDX1, PRDX4, and PRDX6 in most histological glioma types compared to the non-tumor tissues, while PRDX2, PRDX3 and PRDX5 expression remained unaltered. The expression of PRDX4 and PRDX6 was higher in mesenchymal than proneural and classical glioma subtypes. Moreover, lower expression of PRDX1, PRDX4 and PRDX6 was observed in tumors with a glioma CpG island methylator phenotype (G-CIMP) compared to non-G-CIMP tumors, as well as in isocitrate dehydrogenase (IDH) mutant and 1p/19q co-deleted gliomas compared to the wild-type counterparts. High expression of PRDX1, PRDX4 or PRDX6 correlated with poor survival of glioma patients. PRDX1 and PRDX6 displayed a positive correlation with different immune cell population in low grade gliomas and, to a lesser extent, in glioblastoma. PRDX1 expression exhibited negative correlation with DNA methylation. These results indicate that high expression of PRDX1, PRDX4 and PRDX6 is associated with poor outcome in gliomas.
Prognostic Role of PD-L1 Expression in Oral Squamous Cell Carcinoma Varies by Oral Compartments and Immunostaining Patterns: A Meta-analysis

Xiao-Guo Hua,Jiong Li,Cai Chen,Rui Hu,Xiqiu Feng,Yong Jiang,Xiu-Jun Zhang

DOI: https://doi.org/10.22541/au.167458077.70590844/v1

2023-01-01

Abstract:Blocking the PD-L1/PD-1 pathway efficiently enhanced antitumor immunity that reduced tumour growth and improved survival, whereas the prognostic roles of PD-L1 positivity in oral squamous cell carcinoma (OSCC) were controversial. This study aimed to determine the clinicopathological and prognostic significance of PD-L1 expression in tumor cells (TCs) or tumor-infiltrating lymphocytes (TILs) of OSCC. The systematic retrieve was performed for seeking suitable studies through PubMed, Web of Science, the Cochrane Library and Scopus. 46 studies were ultimately included in the meta-analysis. This study showed that the levels of PD-L1 expression in TCs were relatively high in femal patients (P <0.001), non-smoker (P <0.001), non-drinkers (P =0.037), advanced stage (P =0.028), N+ status (P =0.027), and tumours with high levels of PD-1 (P =0.024), and CD8+ (P =0.022). High PD-L1 expression in TCs had significant effect on worse LRFS (P=0.004), and also was more likely to have worse OS in Asia (P =0.018). Both DSS (P =0.035) and DFS (P =0.003), at a 5% cut-off of PPC, had positive association with high PD-L1 expression. The results of OS showed that a worse prognosis for 5H1 (P =0.032), and a favourable prognosis for 22C3(P =0.001). E1L3N was shown to be associated with an worse DSS (P =0.014). High expressions of PD-L1 in TCs had a worse OS (P =0.023) and DFS (P =0.003) in OSCC of the tongue. Consequently, future study should especially consider oral compartments and methods for PD-L1 immunostaining as confounding factors when observing PD-L1 of response to anti-PD1 therapy.
An Oxidative Stress-Related Prognostic Signature for Indicating the Immune Status of Oral Squamous Cell Carcinoma and Guiding Clinical Treatment

Wei Lu,Changwei Yin,Tianqi Zhang,Yihua Wu,Shengyun Huang

DOI: https://doi.org/10.3389/fgene.2022.977902

IF: 3.7

2022-01-01

Frontiers in Genetics

Abstract:Oral squamous cell carcinoma (OSCC) is the eighth most common cancer worldwide and presents high mortality. Oxidative stress, caused by reactive oxygen species accumulation, plays a crucial role in tumorigenesis, cancer progression, and drug resistance. Nevertheless, the specific prognostic and clinical values of oxidative stress-related genes (OSGs) in OSCC remain unclear. Here, we developed an oxidative stress-related prognostic signature according to mRNA expression data from The Cancer Genome Atlas (TCGA) database and evaluated its connections with the prognosis, clinical features, immune status, immunotherapy, and drug sensitivity of OSCC through a series of bioinformatics analyses. Finally, we filtered out six prognostic OSGs to construct a prognostic signature. On the basis of both TCGA-OSCC and GSE41613 cohorts, the signature was proven to be an independent prognostic factor with high accuracy and was confirmed to be an impactful indicator for predicting the prognosis and immune status of patients with OSCC. Additionally, we found that patients with high-risk scores may obtain greater benefit from immune checkpoint therapy compared to those with low-risk scores, and the risk score presented a close interaction with the tumor microenvironment and chemotherapy sensitivity. The prognostic signature may provide a valid and robust predictive tool that could predict the prognosis and immune status and guide clinicians to develop personalized therapeutic strategies for patients with OSCC.
The oncogenic role and prognostic value of PXDN in human stomach adenocarcinoma

Yuan Tian,Shenghui Qiu,Song Yang,Yuanjian Jiang,Hao Hu,Chengcheng Yang,Jinyong Cao,Shaomin Chen,Mingqing Hao,Hongling Li,Jianlin Zhu

DOI: https://doi.org/10.1186/s12885-024-13097-6

IF: 4.638

2024-11-29

BMC Cancer

Abstract:Stomach adenocarcinoma (STAD) is known for its high prevalence and poor prognosis, which underscores the need for novel therapeutic targets. Peroxidasin (PXDN), an enzyme with peroxidase activity, has been linked to cancer development in previous studies. However, its specific role in STAD is not well understood. In our study, we used public databases and clinical specimens to determine that PXDN expression is significantly elevated in STAD tissues and serves as an independent prognostic marker for patient outcomes. Our in vitro assays demonstrated that silencing PXDN significantly reduced STAD cell proliferation, invasion, and migration. Mechanistically, we found that PXDN promotes epithelial‒mesenchymal transition and angiogenesis in STAD cells and may be regulated by the PI3K/AKT pathway. Further analysis revealed that PXDN levels affect the sensitivity of STAD cells to various chemotherapeutic and small molecule drugs. Additionally, we observed a significant association between PXDN levels and the abundances of various immune cell types in patients with STAD. Our study highlighted a strong link between PXDN levels and the tumor immune microenvironment (TIM), suggesting that PXDN is a useful metric for evaluating the response to immune checkpoint inhibitors. Moreover, we found that PXDN is significantly associated with multiple immune checkpoints. In summary, our findings indicate that PXDN plays a critical role in STAD and that its level could serve as a potential prognostic biomarker. Thus, targeting PXDN may represent an effective treatment strategy for STAD.

oncology
Expression and clinical role of PRDX6 in lung adenocarcinoma

Zixin Chen,Junjun Lin,Huifang Wang,Jing Wang,Zhou Zhang

DOI: https://doi.org/10.1177/03000605241236276

2024-03-21

Journal of International Medical Research

Abstract:Journal of International Medical Research, Volume 52, Issue 3, March 2024. ObjectiveTo explore the levels of expression and clinical role of peroxiredoxin 6 (PRDX6) in lung adenocarcinoma.MethodsThis retrospective study used a series of bioinformatics methods to detect the levels of expression of and mutations in the PRDX6 gene in a range of cancers and lung adenocarcinoma. Immunohistochemistry was used to verify the levels of expression of PRDX6 protein in samples of lung adenocarcinoma compared with normal adjacent tissue. The effect of PRDX6 gene knockdown on the in vitro proliferation of a lung adenocarcinoma cell line was measured. Bioinformatics methods were used to determine the diagnostic value and impact on survival of the PRDX6 gene in patients with lung adenocarcinoma.ResultsThe results showed that the PRDX6 gene was highly expressed in lung adenocarcinoma and there were five mutations at different sites on the gene. PRDX6 promoted the proliferation of the lung adenocarcinoma cell line. The survival duration of lung adenocarcinoma patients with high levels of PRDX6 gene expression was significantly shorter than that of patients with low PRDX6 gene expression.ConclusionPRDX6 is highly expressed in lung adenocarcinoma and higher levels of expression of the PRDX6 gene were associated with a poorer prognosis.

pharmacology & pharmacy,medicine, research & experimental
Construction of a PANoptosis-related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Ovarian Cancer

Yonghong Liu,Guizhen Lyu

DOI: https://doi.org/10.2174/0109298673314864240829064622

2024-09-06

Abstract:Background: The PANoptosis pathway is a recently identified mechanism of cellular death that involves the interaction and synchronization among cellular pyroptosis, apoptosis, and necrosis. More and more evidence suggests that PANoptosis is involved in the development and treatment of cancer. However, a comprehensive understanding of the influence of PANoptosis genes on prognostic value, tumor microenvironment characteristics, and therapeutic outcomes in patients with ovarian cancer (OC) remains incomplete. Objective: The present work was designed to devise a PANoptosis signature for OC prognosis and explore its potential molecular function. Methods: For this study, we obtained RNA sequencing and clinical data for ovarian cancer from the Cancer Genome Atlas (TCGA) and the GSE32062 cohort. Somatic variants of PANoptosis-related genes (PRGs) in OC were analyzed using GSCA. TCGA-OC and GSE32062 were used to construct training and validation cohorts for the model. Differential expression and correlation analyses were performed following the screening of genes with prognostic ability using univariate Cox analysis. Least Absolute Shrinkage nd Selection Operator (LASSO) regression was performed to construct PRG signature based on genes that were differentially expressed and correlated with prognosis. CIBER-SORT and ESTIMATE were used to analyze the relationship between the PRGs signature and immune infiltration. TIDE was used to analyze the relationship between the PRG signature and immune checkpoint genes. OncoPredict was used to analyze the relationship between the PRG signature and the drug sensitivity. Quantitative real-time PCR (qRT-PCR) was used to validate the expression of PRGs in OC. Results: The PRG signature was constructed using three prognostic genes (AIM2, APAF1, and ZBP1) in both TCGA-OC. The results showed that the PRGs signature had an AUC of 0.521, 0.546, and 0.598 in TCGA-OC and 0.620, 0.586, and 0.579 in GSE32062 to predict to predict OS at 1-, 3-, and 5-year intervals. Furthermore, a higher PRG signature risk score was significantly associated with shorter OS (HR = 1.693, 95% CI: 1.303 - 2.202, p = 8.34 × 10^-5 in TCGA-OC and HR = 1.63, 95% CI: 1.13 - 2.35, p = 0.009 in GSE32062). The risk score was identified as the independent prognostic factor for OC. Patients categorized according to their risk score exhibited notable variations in immune status, response to immunotherapy, and sensitivity to drugs. AIM2, APAF1, and ZBP1 were significantly aberrantly expressed in OC cell lines. Conclusion: The PRG signature has the potential to serve as a prognostic predictor for OC and to provide new insights into OC treatment.
XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC

Ying Han,Ying Peng,Haofeng Xiong,Liujun Zeng,Tianyi Zhang,Kun Xia,Xin Hu,Tong Su

DOI: https://doi.org/10.1002/cam4.70076

Abstract:Background: Exportin 1 (XPO1) is a nuclear export protein that facilitates the transportation of various substances. XPO1 promotes tumor development as a poor prognostic factor in a variety of tumors and is a therapeutic target for screening inhibitors. However, the role of XPO1 in oral squamous cell carcinoma (OSCC) has yet to be determined. Methods: The expression patterns of XPO1 mRNA in OSCC were investigated using bioinformatics tools, and the expression levels of XPO1 protein in OSCC specimens were confirmed by immunohistochemical assays. Survival analysis was conducted to evaluate the impact of XPO1 on prognosis. GO and KEGG enrichment analyses were utilized to uncover the signaling pathways mediated by XPO1. Additionally, we examined the association between XPO1 and AKT/MAPK/TGFBR1 and immune infiltration. Results: XPO1 mRNA and protein expression levels were significantly enhanced in OSCC and associated with OSCC severity. Enhanced XPO1 expression was indicative of poor survival. Functional analysis showed that XPO1 mediated pathways associated with cell cycle and DNA replication and reduced immune infiltration in OSCC. Additionally, XPO1 mRNA and protein expression levels had significant positive relationships with AKT/MAPK/TGFBR1. Conclusions: XPO1, as a marker of poor prognosis in OSCC, can promote OSCC through AKT/MAPK/TGFBR1.

A simple spatial alternation task for assessing memory function in zebrafish

The Prognostic Values of the Peroxiredoxins Family in Ovarian Cancer

Review article: indeterminate colitis – definition, diagnosis and management

The High Expression of PTPRH is Associated with Poor Prognosis of Human Lung Adenocarcinoma

The interaction of PRDX1 with Cofilin promotes oral squamous cell carcinoma metastasis

The Prognosis Of Peroxiredoxin Family In Breast Cancer

Systematic Characterization of Prognostic Values of Peroxiredoxin Family in Gastric Cancer

Peroxiredoxin 1 regulates crosstalk between pyroptosis and autophagy in oral squamous cell carcinoma leading to a potential pro-survival

Peroxiredoxin 2 as a potential prognostic biomarker associated with angiogenesis in cervical squamous cell cancer

A Systematic Pan-Cancer Analysis of PXDN As a Potential Target for Clinical Diagnosis and Treatment

Erythroblast transformation‐specific‐related gene promotes metastasis of oral squamous cell carcinoma by transcriptionally upregulating peroxiredoxin 1

The Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor microenvironment in Hepatocellular carcinoma

Integrative analysis the characterization of peroxiredoxins in pan-cancer

Pyroptosis Related Genes Signature Predicts Prognosis and Immune Infiltration of Tumor Microenvironment in Hepatocellular Carcinoma

Comprehensive analysis of the expression levels and prognostic values of PRDX family genes in glioma

Prognostic Role of PD-L1 Expression in Oral Squamous Cell Carcinoma Varies by Oral Compartments and Immunostaining Patterns: A Meta-analysis

An Oxidative Stress-Related Prognostic Signature for Indicating the Immune Status of Oral Squamous Cell Carcinoma and Guiding Clinical Treatment

The oncogenic role and prognostic value of PXDN in human stomach adenocarcinoma

Expression and clinical role of PRDX6 in lung adenocarcinoma

Construction of a PANoptosis-related Prognostic Signature for Predicting Prognosis, Tumor Microenvironment, and Immune Response in Ovarian Cancer

XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC